Compare Stocks: CELC, ASND, SMMT, and EXEL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$236.72 -1.0%	$254.83	$186.05 ▼ $282.15	$14.77B	0.35	670,253 shs	1.56 million shs
CELC Celcuity	$80.61 -5.1%	$90.18	$44.42 ▼ $151.02	$3.94B	0.19	770,005 shs	1.41 million shs
EXEL Exelixis	$58.36 -0.2%	$55.44	$33.76 ▼ $59.72	$14.46B	0.42	1.94 million shs	5.24 million shs
SMMT Summit Therapeutics	$17.85 +0.7%	$14.71	$12.07 ▼ $29.23	$14.24B	-1.24	5.98 million shs	13.06 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	-0.97%	-10.17%	-8.82%	+2.55%	+18.60%
CELC Celcuity	-5.06%	-3.40%	-13.91%	-8.15%	+47.64%
EXEL Exelixis	-0.22%	+3.99%	+7.30%	+12.43%	+44.31%
SMMT Summit Therapeutics	+0.73%	+1.71%	+36.16%	+29.82%	-1.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$236.72 -1.0%	$254.83	$186.05 ▼ $282.15	$14.77B	0.35	670,253 shs	1.56 million shs
CELC Celcuity	$80.61 -5.1%	$90.18	$44.42 ▼ $151.02	$3.94B	0.19	770,005 shs	1.41 million shs
EXEL Exelixis	$58.36 -0.2%	$55.44	$33.76 ▼ $59.72	$14.46B	0.42	1.94 million shs	5.24 million shs
SMMT Summit Therapeutics	$17.85 +0.7%	$14.71	$12.07 ▼ $29.23	$14.24B	-1.24	5.98 million shs	13.06 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	-0.97%	-10.17%	-8.82%	+2.55%	+18.60%
CELC Celcuity	-5.06%	-3.40%	-13.91%	-8.15%	+47.64%
EXEL Exelixis	-0.22%	+3.99%	+7.30%	+12.43%	+44.31%
SMMT Summit Therapeutics	+0.73%	+1.71%	+36.16%	+29.82%	-1.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	3.00	Buy	$310.75	31.27% Upside
CELC Celcuity	2.83	Moderate Buy	$154.75	91.97% Upside
EXEL Exelixis	2.35	Hold	$50.29	-13.84% Downside
SMMT Summit Therapeutics	2.47	Hold	$25.91	45.14% Upside

Current Analyst Ratings Breakdown

Latest CELC, ASND, SMMT, and EXEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	CELC Celcuity	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$157.00
9/16/2026	ASND Ascendis Pharma A/S	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$344.00
9/15/2026	ASND Ascendis Pharma A/S	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$287.00
9/14/2026	EXEL Exelixis	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/11/2026	EXEL Exelixis	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/10/2026	ASND Ascendis Pharma A/S	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$344.00
9/10/2026	ASND Ascendis Pharma A/S	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/10/2026	ASND Ascendis Pharma A/S	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/9/2026	SMMT Summit Therapeutics	Summit Redstone Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
9/8/2026	SMMT Summit Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$33.00
9/3/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$814.57M	18.13	N/A	N/A	($2.97) per share	-79.70
CELC Celcuity	N/A	N/A	N/A	N/A	$2.17 per share	N/A
EXEL Exelixis	$2.32B	6.23	$3.03 per share	19.28	$8.06 per share	7.24
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$258M	$12.89	18.36	26.69	N/A	70.99%	32.54%	7.71%	11/11/2026 (Estimated)
CELC Celcuity	-$177.04M	-$4.30	N/A	N/A	N/A	N/A	-350.78%	-41.54%	11/11/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	18.35	15.69	1.74	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
SMMT Summit Therapeutics	-$1.08B	-$1.12	N/A	N/A	N/A	N/A	-168.94%	-141.92%	10/19/2026 (Estimated)

Latest CELC, ASND, SMMT, and EXEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ASND Ascendis Pharma A/S	$1.71	$1.0270	-$0.6830	$3.23	$376.75 million	$387.22 million
8/13/2026	Q2 2026	CELC Celcuity	-$1.16	-$1.44	-$0.28	-$1.44	$4.42 million	N/A
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
7/23/2026	Q2 2026	SMMT Summit Therapeutics	-$0.2744	-$0.28	-$0.0056	-$0.28	$0.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
CELC Celcuity	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	0.27	2.99	2.32
CELC Celcuity	6.04	8.93	8.93
EXEL Exelixis	N/A	3.46	3.38
SMMT Summit Therapeutics	N/A	6.96	6.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
CELC Celcuity	63.33%
EXEL Exelixis	85.27%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
CELC Celcuity	13.33%
EXEL Exelixis	2.60%
SMMT Summit Therapeutics	83.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
CELC Celcuity	155	48.93 million	42.41 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
SMMT Summit Therapeutics	265	797.75 million	131.63 million	Optionable

CELC, ASND, SMMT, and EXEL Headlines

Recent News About These Companies

Summit Therapeutics: It's Okay Not To Have An Answer

September 17 at 9:32 AM | seekingalpha.com

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Azenta (AZTA)

September 15, 2026 | theglobeandmail.com

Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 7% - Should You Sell?

September 15, 2026 | marketbeat.com

Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients

September 15, 2026 | businesswire.com

Ivonescimab cuts death risk 27% vs. pembrolizumab in lung cancer

September 13, 2026 | streetinsider.com

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso ...

September 13, 2026 | streetinsider.com

Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial

September 13, 2026 | msn.com

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu

September 13, 2026 | gurufocus.com

September 13, 2026 | businesswire.com

Hsbc Holdings PLC Purchases Shares of 120,560 Summit Therapeutics PLC $SMMT

September 12, 2026 | marketbeat.com

Summit Therapeutics PLC (SMMT)

September 10, 2026 | fr.investing.com

Summit Therapeutics Shares Rise After Upgrade From Jefferies

September 9, 2026 | marketscreener.comM

Summit Therapeutics shares gain after Jefferies upgrades stock to buy

September 9, 2026 | msn.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - Time to Buy?

September 9, 2026 | marketbeat.com

Summit Therapeutics PLC $SMMT Shares Bought by Wellington Management Group LLP

September 9, 2026 | marketbeat.com

Summit (SMMT) Says Akeso Reported a HARMONi-2 Overall-Survival Benefit Against Pembrolizumab

September 8, 2026 | insidermonkey.com

Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress

September 7, 2026 | insidermonkey.com

Seven Fleet Capital Management LP Acquires Shares of 73,300 Summit Therapeutics PLC $SMMT

September 5, 2026 | marketbeat.com

Bank of New York Mellon Corp Takes $6.28 Million Position in Summit Therapeutics PLC $SMMT

September 5, 2026 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Raised to Hold at Wall Street Zen

September 5, 2026 | marketbeat.com

SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China

September 4, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELC, ASND, SMMT, and EXEL Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

$236.72 -2.32 (-0.97%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$238.46 +1.74 (+0.74%)

As of 09/18/2026 07:30 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Celcuity NASDAQ:CELC

$80.61 -4.30 (-5.06%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$81.08 +0.47 (+0.58%)

As of 09/18/2026 07:54 PM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Exelixis NASDAQ:EXEL

$58.36 -0.13 (-0.22%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$58.74 +0.38 (+0.66%)

As of 09/18/2026 07:30 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Summit Therapeutics NASDAQ:SMMT

$17.85 +0.13 (+0.73%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$17.79 -0.06 (-0.32%)

As of 09/18/2026 07:49 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CELC, ASND, SMMT, and EXEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CELC, ASND, SMMT, and EXEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CELC, ASND, SMMT, and EXEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELC, ASND, SMMT, and EXEL Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

Celcuity NASDAQ:CELC

Exelixis NASDAQ:EXEL

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CELC, ASND, SMMT, and EXEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CELC, ASND, SMMT, and EXEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CELC, ASND, SMMT, and EXEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELC, ASND, SMMT, and EXEL Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

Celcuity NASDAQ:CELC

Exelixis NASDAQ:EXEL

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools